Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Webcast:

UX beyond the website: Insights for the age of omnichannel

Inizio

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

- PMLiVE

Lilly to target difficult-to-treat disease through tie-up with Lycia

Lilly will use Lycia Therapeutics’ novel technology to inhibit “intractable” targets in its therapeutic areas of focus, including immunology and pain

- PMLiVE

Pfizer/BioNTech file for FDA approval for COVID-19 booster jab

New data shows third dose boosts antibodies by more than three times

10,000 autistic people to take part in the UK’s largest study of autism

An ambitious new research project, Spectrum 10K, has launched that will recruit 10,000 autistic individuals and their relatives living in the UK

- PMLiVE

GSK/Merck KGgA cancer drug fails in third trial

Fusion protein, bintrafusp alfa – the centrepiece of the 2019 GSK/Merck partnership – has failed to meet its latest trial endpoint and the trial is to be discontinued

- PMLiVE

Protection against COVID-19 reduces over time in fully vaccinated, according to new real-world study

The Zoe COVID-19 Study shows protection could fall by up to 14%

- PMLiVE

Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting

The company will use data from the SOLOIST and SCORED trials as part of a new drug application later this year

- PMLiVE

FDA’s approval of Pfizer/BioNTech’s COVID-19 vaccine “is a milestone” says acting FDA commissioner Janet Woodcock

After more than a billion doses have been given worldwide, Comirnaty is now officially approved for people aged 16 and over in the US

- PMLiVE

FDA to consider BMS’ Orencia for graft versus host disease

Leukaemia patients who receive stem cell transplant may gain access to Orencia by the end of the year

- PMLiVE

Pfizer to acquire Canadian immuno-oncology company Trillium in a deal worth $2.6bn

The deal will strengthen Pfizer’s oncology offering and follows an investment of $25m in Trillium made by Pfizer in January

A holistic approach to managing pressure in MedComms

Fox&Cat

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links